Communiqués Amplia Therapeutics Limited

Actions

ATX

AU0000023822

Recherche biotechnologique et médicale

Temps Différé Australian S.E. 07:32:16 14/08/2026			Varia. 5j.	Varia. 1 janv.
0,1500 ^AUD	+3,45 %		0,00 %	-

04/08	Amplia Therapeutics va évaluer une thérapie combinée contre le cancer du poumon non à petites cellules en collaboration avec Eli Lilly ; l'action grimpe de 7 %	MT
04/08	Amplia Therapeutics va évaluer une thérapie combinée contre le cancer du poumon non à petites cellules en collaboration avec Eli Lilly	MT

Communiqués

04/08	Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer	GL
31/07	Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online	GL
09/07	Amplia Announces Publication of New FAK Inhibitor Patent Application	GL
07/07	Amplia Announces Changes to Board's Leadership Roles	AQ
07/07	Amplia Announces Appointment of Brett Carter to Board	GL
06/07	Amplia Announces Changes to Board’s Leadership Roles	GL
22/06	Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer	GL
19/05	Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib	GL
09/05	Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study	GL
22/04	Accent Trial Mature Data Presented at International Conference	GL
23/03	Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial	GL
11/03	Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th	AQ
09/03	Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models	GL
11/02	Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial	GL
30/01	Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025	GL
22/01	NARMAFOTINIB Large-Scale Manufactre Complete	GL
12/01	ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM	GL
23/12	Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium	GL
19/12	Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors	GL
12/12	Additional Confirmed Response Reported as Part of Amplia Investor Presentation	GL
08/12	Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
03/12	Key Narmafotinib Patent Granted in the U.S.	GL
14/02/24	Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial	AQ
22/05/23	Amplia secures funding to assess AMP945 topical applications	AQ
30/01/23	Amplia Therapeutics CEO outlines 2023 milestones	AQ